Design and Development of a Behaviorally Active Recombinant Neurotrophic Factor
Open Access
- 1 December 2020
- journal article
- research article
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 14, 5393-5403
Abstract
Introduction: Carbamoylated erythropoietin (CEPO) is a chemically engineered, nonhematopoietic derivative of erythropoietin (EPO) that retains its antidepressant and pro-cognitive effects, which are attributed to the increased expression of neurotrophic factors like brain derived neurotrophic factor (BDNF), in the central nervous system. However, the chemical modification process which produces CEPO from erythropoietin (EPO) requires pure EPO as raw material, is challenging to scale-up and can also cause batch-to-batch variability. To address these key limitations while retaining its behavioral effects, we designed, expressed and analyzed a triple, glutamine, substitution recombinant mimetic of CEPO, named QPO. Methods and Materials: We employ a combination of computational structural biology, molecular, cellular and behavioral assays to design, produce, purify and test QPO. Results: QPO was shown to be a nonhematopoietic polypeptide with significant antidepressant-like and pro-cognitive behavioral effects in rodent assays while significantly upregulating BDNF expression in-vitro and in-vivo. The in-silico binding affinity analysis of QPO bound to the EPOR/EPOR homodimer receptor shows significantly decreased binding to Active Site 2, but not Active Site 1, of EPOR. Discussion: The results of the behavioral and gene expression analysis imply that QPO is a successful CEPO mimetic protein and potentially acts via a similar neurotrophic mechanism, making it a drug development target for psychiatric disorders. The decreased binding to Active Site 2 could imply that this active site is not involved in neuroactive signaling and could allow the development of a functional innate repair receptor (IRR) model. Substituting the three glutamine substitution residues with arginine (RPO) resulted in the loss of behavioral activity, indicating the importance of glutamine residues at those positions.Keywords
This publication has 25 references indexed in Scilit:
- Effects of Erythropoietin on Hippocampal Volume and Memory in Mood DisordersBiological Psychiatry, 2015
- Recombinant Human Erythropoietin for Treating Treatment-Resistant Depression: A Double-Blind, Randomized, Placebo-Controlled Phase 2 TrialNeuropsychopharmacology, 2013
- Treatment-resistant depression: therapeutic trends, challenges, and future directionsPatient Preference and Adherence, 2012
- Erythropoietin Induction by Electroconvulsive Seizure, Gene Regulation, and Antidepressant-Like Behavioral EffectsBiological Psychiatry, 2009
- Symmetric Signaling by an Asymmetric 1 Erythropoietin: 2 Erythropoietin Receptor ComplexMolecular Cell, 2009
- Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietinProceedings of the National Academy of Sciences, 2008
- Neuroprotective effects of erythropoietin in the rat hippocampus after pilocarpine-induced status epilepticusNeurobiology of Disease, 2007
- Scalable molecular dynamics with NAMDJournal of Computational Chemistry, 2005
- Derivatives of Erythropoietin That Are Tissue Protective But Not ErythropoieticScience, 2004
- The role of carbohydrate in recombinant human erythropoietinEuropean Journal of Biochemistry, 1990